{"id":"W2168849655","doi":"10.2147/btt.s1832","title":"Erlotinib in the treatment of advanced pancreatic cancer","year":2008,"lang":"en","type":"article","venue":"Biologics","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Gemcitabine; Pancreatic cancer; Medicine; Oncology; Internal medicine; Erlotinib Hydrochloride; Malignancy; Epidermal growth factor receptor; Clinical trial; Cancer; Chemotherapy; EGFR inhibitors; Targeted therapy; Tyrosine-kinase inhibitor; Cabozantinib; Pharmacology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001255447,0.0000765279,0.0003408789,0.00003972737,0.00003903775,7.297199e-7,0.00006878192,0.00007279489,0.000104349],"category_scores_gemma":[0.00009369633,0.000035951,0.0000523567,0.0001506164,0.0001939402,0.000009192496,0.000006285641,0.00005887763,0.0000117093],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000744969,"about_ca_system_score_gemma":0.0001442749,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002336365,"about_ca_topic_score_gemma":0.00005385039,"domain_scores_codex":[0.9993532,0.00008413196,0.0001742436,0.000114373,0.0001006047,0.0001734837],"domain_scores_gemma":[0.9994182,0.0002762982,0.00004556435,0.0001896849,0.00003857127,0.00003166173],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002502556,0.0005292736,0.9897417,0.00001433475,0.00003675985,0.00007423127,0.001245258,0.000002929764,0.00152702,0.0001257104,0.0001730166,0.006279486],"study_design_scores_gemma":[0.001763536,0.002869438,0.9842066,0.00002617384,0.00005312058,0.00005220304,0.0004641391,0.00005922271,0.0005937996,0.00008378114,0.00978193,0.00004610086],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913985,0.002582816,0.000005781711,0.0006349331,0.00003304709,0.0005368291,0.000007659509,0.00001028901,0.004790218],"genre_scores_gemma":[0.9816365,0.016283,0.0007009559,0.000189697,0.00005824597,0.0001536056,0.00001034898,0.000003573268,0.0009640432],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01370019,"threshold_uncertainty_score":0.1466039,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1107101820081687,"score_gpt":0.3985478263578194,"score_spread":0.2878376443496507,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}